Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938258 | 0.86 | HTT (0.53) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL1704181 | 0.85 | ALDH1A1 (0.44) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL30559973 | 0.83 | CA1 (0.58) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL20560682 | 0.83 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL422893 | 0.83 | CA1 (0.58) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL23997341 | 0.80 | HPGD (0.51) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL30336857 | 0.80 | HPGD (0.51) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL28007482 | 0.80 | CA1 (0.51) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL1721489 | 0.80 | HTT (0.64) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL5913136 | 0.79 | ALDH1A1 (0.51) | NPC1RAB9ASMN1; SMN2PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| EP-4146644-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2021226003-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | disclosed |
| EP-3743070-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3720852-A1 | FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2 | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-10-14 | — | — | EP | disclosed |
| US-20200308168-A1 | FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2 | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-10-01 | — | — | US | disclosed |
| US-10428049-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-9828339-B2 | Biphenyl derivatives and methods for preparing same | DONG-A ST CO., LTD (KR) | 2017-11-28 | — | — | US | disclosed |
| US-20170001983-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG-A ST CO., LTD (KR) | 2016-06-23 | — | — | US | disclosed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | disclosed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015016511-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | 동아에스티 주식회사 (KR) | 2015-02-05 | — | — | WO | disclosed |
| EP-1711183-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-04-01 | — | — | EP | disclosed |
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | LAINE DRAMANE I | 2008-10-09 | — | — | US | disclosed |
| EP-1711183-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005067537-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | CHRM2, CHRM3, CHRM5 | NPC1 2102/4885RAB9A 814/4885SMN1; SMN2 1664/4885 |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, MAP3K1 | NPC1 1305/4885RAB9A 1262/4885SMN1; SMN2 1760/4885 |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | NPC1 657/4885RAB9A 3126/4885SMN1; SMN2 3247/4885 |
| US-10428049-B2 | TRPA1 modulators | TRPA1, TRPV1, TRPV2 | NPC1 709/4885RAB9A 3349/4885SMN1; SMN2 859/4885 |
| US-20170001983-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | NPC1 709/4885RAB9A 3349/4885SMN1; SMN2 859/4885 |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | NPC1 1305/4885RAB9A 1262/4885SMN1; SMN2 1760/4885 |
| US-20200308168-A1 | FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2 | CHRM2, CHRM3, CHRM5 | NPC1 4519/4885RAB9A 3359/4885SMN1; SMN2 1439/4885 |
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | NPC1 2708/4885RAB9A 2952/4885SMN1; SMN2 2627/4885 |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | NPC1 1305/4885RAB9A 1262/4885SMN1; SMN2 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.